These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 27901595)

  • 1. Conflict of Interest Policies and Industry Relationships of Guideline Development Group Members: A Cross-Sectional Study of Clinical Practice Guidelines for Depression.
    Cosgrove L; Krimsky S; Wheeler EE; Peters SM; Brodt M; Shaughnessy AF
    Account Res; 2017; 24(2):99-115. PubMed ID: 27901595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conflicts of interest and the quality of recommendations in clinical guidelines.
    Cosgrove L; Bursztajn HJ; Erlich DR; Wheeler EE; Shaughnessy AF
    J Eval Clin Pract; 2013 Aug; 19(4):674-81. PubMed ID: 23731207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financial Relationships between Organizations That Produce Clinical Practice Guidelines and the Biomedical Industry: A Cross-Sectional Study.
    Campsall P; Colizza K; Straus S; Stelfox HT
    PLoS Med; 2016 May; 13(5):e1002029. PubMed ID: 27244653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study.
    Neuman J; Korenstein D; Ross JS; Keyhani S
    BMJ; 2011 Oct; 343():d5621. PubMed ID: 21990257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conflicts of interest and disclosure in the American Psychiatric Association's Clinical Practice Guidelines.
    Cosgrove L; Bursztajn HJ; Krimsky S; Anaya M; Walker J
    Psychother Psychosom; 2009; 78(4):228-32. PubMed ID: 19401623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conflicts of Interest in Clinical Guidelines: Update of U.S. Preventive Services Task Force Policies and Procedures.
    Ngo-Metzger Q; Moyer V; Grossman D; Ebell M; Woo M; Miller T; Brummer T; Chowdhury J; Kato E; Siu A; Phillips W; Davidson K; Phipps M; Bibbins-Domingo K
    Am J Prev Med; 2018 Jan; 54(1S1):S70-S80. PubMed ID: 29254528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating Industry Payments Among Dermatology Clinical Practice Guidelines Authors.
    Checketts JX; Sims MT; Vassar M
    JAMA Dermatol; 2017 Dec; 153(12):1229-1235. PubMed ID: 29049553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conflicts of interest in biomedical research--the FASEB guidelines.
    Brockway LM; Furcht LT;
    FASEB J; 2006 Dec; 20(14):2435-8. PubMed ID: 17142792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase.
    Shnier A; Lexchin J; Romero M; Brown K
    BMC Health Serv Res; 2016 Aug; 16(a):383. PubMed ID: 27528247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.
    Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T
    JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conflicts of interest in psychiatry: strategies to cultivate literacy in daily practice.
    Shimazawa R; Ikeda M
    Psychiatry Clin Neurosci; 2014 Jul; 68(7):489-97. PubMed ID: 24802771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten steps to developing a national agenda to address financial conflicts of interest in industry sponsored clinical research.
    Tereskerz PM; Moreno J
    Account Res; 2005; 12(2):139-55. PubMed ID: 16220626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and Disclosure of Potential Conflicts of Interest in Dermatology Patient Advocacy Organizations.
    Li DG; Singer S; Mostaghimi A
    JAMA Dermatol; 2019 Apr; 155(4):460-464. PubMed ID: 30698625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Financial contributions to guideline group members from industry: An analysis based on the US Open Payments database].
    Anjos DRD; Eisch E; Mathes T
    Z Evid Fortbild Qual Gesundhwes; 2020 Aug; 153-154():39-43. PubMed ID: 32553895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Policies on faculty conflicts of interest at US universities.
    Cho MK; Shohara R; Schissel A; Rennie D
    JAMA; 2000 Nov; 284(17):2203-8. PubMed ID: 11056591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study.
    Elder K; Turner KA; Cosgrove L; Lexchin J; Shnier A; Moore A; Straus S; Thombs BD
    CMAJ; 2020 Jun; 192(23):E617-E625. PubMed ID: 32538799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tripartite conflicts of interest and high stakes patent extensions in the DSM-5.
    Cosgrove L; Krimsky S; Wheeler EE; Kaitz J; Greenspan SB; DiPentima NL
    Psychother Psychosom; 2014; 83(2):106-13. PubMed ID: 24458102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Financial ties between DSM-IV panel members and the pharmaceutical industry.
    Cosgrove L; Krimsky S; Vijayaraghavan M; Schneider L
    Psychother Psychosom; 2006; 75(3):154-60. PubMed ID: 16636630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decoding disclosure: Comparing conflict of interest policy among the United States, France, and Australia.
    Grundy Q; Habibi R; Shnier A; Mayes C; Lipworth W
    Health Policy; 2018 May; 122(5):509-518. PubMed ID: 29605526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Conflicts of interest and clinical drug trials -- impact of the pharmaceutical industry and the impingement on the integrity of medical science].
    Ludwig WD; Hildebrandt M; Schott G
    Z Evid Fortbild Qual Gesundhwes; 2009; 103(3):149-54. PubMed ID: 19554889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.